Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Piet Borst

Showing results (51-60 of 90) with videos related to

Pageof 9
Sort By:
Hepatology (Baltimore, Md.)|October 27, 2005
Altered disposition of acetaminophen in mice with a disruption of the Mrp3 geneJosé E Manautou, Dirk R de Waart, Cindy Kunne, et al.
Molecular and Biochemical Parasitology|June 7, 2005
A minor fraction of base J in kinetoplastid nuclear DNA is bound by the J-binding protein 1Cristiane Bentin Toaldo, Rudo Kieft, Anita Dirks-Mulder, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 2, 2003
The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugsGlen Reid, Peter Wielinga, Noam Zelcer, et al.
Plos One|October 3, 2012
EZN-2208 (PEG-SN38) overcomes ABCG2-mediated topotecan resistance in BRCA1-deficient mouse mammary tumorsSerge A L Zander, Wendy Sol, Lee Greenberger, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|October 29, 2011
Transportomics: screening for substrates of ABC transporters in body fluids using vesicular transport assaysPetra Krumpochova, Sunny Sapthu, Jos F Brouwers, et al.
Molecular Cancer Therapeutics|September 4, 2008
Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosidesCornelia de Wolf, Robert Jansen, Hiroaki Yamaguchi, et al.
Cancer Prevention Research (Philadelphia, Pa.)|July 7, 2012
Lack of ABCG2 shortens latency of BRCA1-deficient mammary tumors and this is not affected by genistein or resveratrolSerge A L Zander, Ariena Kersbergen, Wendy Sol, et al.
Cancer Research|August 6, 2009
Moderate increase in Mdr1a/1b expression causes in vivo resistance to doxorubicin in a mouse model for hereditary breast cancerMarina Pajic, Jayasree K Iyer, Ariena Kersbergen, et al.
Cancer Research|December 17, 2014
BRCA2-deficient sarcomatoid mammary tumors exhibit multidrug resistanceJanneke E Jaspers, Wendy Sol, Ariena Kersbergen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 20, 2017
Selected Alkylating Agents Can Overcome Drug Tolerance of G<sub>0</sub>-like Tumor Cells and Eradicate BRCA1-Deficient Mammary Tumors in MiceMarina Pajic, Sohvi Blatter, Charlotte Guyader, et al.
Pageof 9

Showing results (51-60 of 90) with videos related to

Sort By:
Pageof 9
Hepatology (Baltimore, Md.)|October 27, 2005
Altered disposition of acetaminophen in mice with a disruption of the Mrp3 geneJosé E Manautou, Dirk R de Waart, Cindy Kunne, et al.
Molecular and Biochemical Parasitology|June 7, 2005
A minor fraction of base J in kinetoplastid nuclear DNA is bound by the J-binding protein 1Cristiane Bentin Toaldo, Rudo Kieft, Anita Dirks-Mulder, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 2, 2003
The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugsGlen Reid, Peter Wielinga, Noam Zelcer, et al.
Plos One|October 3, 2012
EZN-2208 (PEG-SN38) overcomes ABCG2-mediated topotecan resistance in BRCA1-deficient mouse mammary tumorsSerge A L Zander, Wendy Sol, Lee Greenberger, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|October 29, 2011
Transportomics: screening for substrates of ABC transporters in body fluids using vesicular transport assaysPetra Krumpochova, Sunny Sapthu, Jos F Brouwers, et al.
Molecular Cancer Therapeutics|September 4, 2008
Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosidesCornelia de Wolf, Robert Jansen, Hiroaki Yamaguchi, et al.
Cancer Prevention Research (Philadelphia, Pa.)|July 7, 2012
Lack of ABCG2 shortens latency of BRCA1-deficient mammary tumors and this is not affected by genistein or resveratrolSerge A L Zander, Ariena Kersbergen, Wendy Sol, et al.
Cancer Research|August 6, 2009
Moderate increase in Mdr1a/1b expression causes in vivo resistance to doxorubicin in a mouse model for hereditary breast cancerMarina Pajic, Jayasree K Iyer, Ariena Kersbergen, et al.
Cancer Research|December 17, 2014
BRCA2-deficient sarcomatoid mammary tumors exhibit multidrug resistanceJanneke E Jaspers, Wendy Sol, Ariena Kersbergen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 20, 2017
Selected Alkylating Agents Can Overcome Drug Tolerance of G<sub>0</sub>-like Tumor Cells and Eradicate BRCA1-Deficient Mammary Tumors in MiceMarina Pajic, Sohvi Blatter, Charlotte Guyader, et al.
Pageof 9